Who is sponsoring NCT02324725?

NCT02324725 is sponsored by University of Pennsylvania.

What condition does NCT02324725 study?

NCT02324725 studies Heroin Dependence, Opioid Dependence.

What is the status of NCT02324725?

NCT02324725 is currently COMPLETED.

Last reviewed 2022-12-30 · How we verify

Biomarkers of Disease and Response to Treatment in Opioid Addiction

NCT02324725 Phase 4 COMPLETED

This study evaluates the biological markers of treatment of opioid dependent individuals with an extended release formulation of the opioid antagonist naltrexone. The biological measures include functional MRI, blood levels of naltrexone and its metabolites, urine toxicology and behavioral tests probing various aspects of personality, memory, reward processing and attention.

Details

Lead sponsor	University of Pennsylvania
Phase	Phase 4
Status	COMPLETED
Enrolment	32
Start date	2011-10
Completion	2021-12

Conditions

Heroin Dependence
Opioid Dependence

Interventions

Naltrexone

Primary outcomes

Brain response to heroin-related visual cues — 1 hour
Brain, behavioral and motivational (e.g. craving) response to audiovisual drug-related and control stimuli (images, smells and sounds) and to standard tasks of decision making, self-appraisal, response inhibition, social interaction and reward processing.

Countries

United States